Latanoprost

Hyderabad: Injectables developer Gland Pharma Q4 FY24-25 revenue from operations reported a year-on-year decline of 7 per cent to ₹1,424 crore. While the quarter’s profit margin remained unchanged at 13 per cent against the corresponding period, the Profit After Tax (PAT) reported a decline of 3 per cent YoY and 9 per cent QoQ to ₹186 crore, down from ₹192 crore recorded in the corresponding period. On both quarter and annual basis, the Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) contracted by 3 per cent to ₹ 347 crore. For the full financial year, the company's revenue reported a margin dip of 1 per cent to ₹5,616 crore while its net profit plummeted by 10 per cent to ₹698.5 crore, down from ₹772.5 crore recorded in the previous fiscal. During the period, the company's profit margin contracted by 2 percentage points to 12 per cent. In FY25, the US business reported muted revenue growth while the revenue from Europe, India and Rest of World declined by 2 per cent, 11 per cent and 4 per cent, respectively. Of the total fiscal earnings, revenue from Gland base business declined by 1 per cent to ₹4,124 crore, while the net profit stood at ₹1,086 crore at a stable margin of 26 per cent. On a regional basis Gland’s base business revenue in the US remained flat, standing at ₹2,976 crore whereas its revenue from India contracted by 11 per cent to ₹248 crore. “FY25 was a year of strategic realignment and investment in future growth. Through the year, we mitigated many challenges and strengthened the core by advancing key pillars of manufacturing, quality, and R&D,” said Srinivas Sadu, Executive Chairman, Gland Pharma. During the period, it launched 31 molecules, including “four new molecules namely Latanoprost, Midazolam Bags RTU, Dexamethasone, and Vancomycin (New Strengths), in Q4 FY25. Gland Pharma also launched its first partnered GLP-1, Liraglutide, in Q4 FY25 and is working to expand its production capacity to 140 million units, up from the current 40 million units As per the company release, discussions with Henlius are progressing well and are expecting revenue generation from the collaboration with Dr Reddy’s in the ongoing fiscal. “Our progress in biologics CDMO and collaborations with leading partners reflect our intent to diversify and grow beyond traditional segments. We remain firmly focused on executing the Cenexi turnaround and leveraging targeted M&A to drive long-term, sustainable value for all stakeholders,” Sadu noted. Outlining the company’s future plans the CEO said, “Our approach involves expanding our core business into new emerging markets, building complex injectables pipeline and through our robust in-house research and development efforts.” Following the announcement of Gland quarter results, the board has recommended a final dividend of ₹18 per equity share for FY25, pending shareholder approval. By Online Bureau ,